A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis

Inclusion Criteria:

1. When signing the informed consent form, the age range is 18 to 75 years old (including threshold), and there is no gender limit.

2. Body mass index (BMI) is between 17.5 and 40.0 kg/m2 (inclusive), with a weight of ≥ 45.0 kg.

3. Insufficient response or intolerance to topical corticosteroids (TCS) or topicalcalcineurin inhibitors (TCI) within the last 6 months of randomization; Insufficientresponse is defined as the failure to achieve and maintain remission or low diseaseactivity (equivalent to vIGA 0=complete clearance to 2=mild) despite the use of amoderate to high efficacy TCS regimen (± TCI if applicable) for at least 28 days orthe longest duration recommended in the drug prescription information (e.g. 14 daysfor super potent TCS), whichever is shorter.

4. Subjects must use topical moisturizers (moisturizers) daily for at least 7consecutive days prior to the baseline visit. Participants should continue to usedaily moisturizers during the study period.

5. Female and male participants with fertility and their partners had no fertilityplans during the study period and within 6 months after the last dose, and agreed totake effective contraceptive measures.

6. Understand and voluntarily sign written informed consent; Willing and able tocomplete planned visits, treatments, examinations, and other procedures (such asdietary requirements, diary card recording, and collection) according to therequirements of the plan.

Exclusion Criteria:

1. Merge other skin diseases that may interfere with the study evaluation, such aspsoriasis, tinea corporis, lupus erythematosus, etc.

2. Systemic anti infective therapy is required for active or chronic recurrentinfections within the 4 weeks prior to the baseline visit.

3. Known or suspected to have a history of immune deficiency disease, other immunerelated diseases, invasive opportunistic infections or associated activetuberculosis.

4. History of severe or recurrent herpes virus infection, such as herpeticencephalitis, disseminated herpes, etc.

5. History of important organ transplantation (such as heart, lung, kidney, liver) orhematopoietic stem cell/bone marrow transplantation.

6. After inquiry, there is a history of lymphoproliferative diseases; Or currentlysuffering from malignant tumors or having a history of malignant tumors (excludingsquamous cell carcinoma in situ of the skin, basal cell carcinoma, and cervicalcancer in situ, which have achieved complete remission after radical treatment formore than 5 years without any signs of recurrence).

7. A family history of sudden death or long QT syndrome, or subjects with a history ofcongenital or drug-induced long QT syndrome.